0
     

Report Added
Report already added
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Drugs In Development, 2022, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 24, 52, 12, 134, 38 and 5 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 10 and 4 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Idiopathic Pulmonary Fibrosis - Overview
Idiopathic Pulmonary Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
Idiopathic Pulmonary Fibrosis - Drug Profiles
Idiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
Idiopathic Pulmonary Fibrosis - Product Development Milestones
Featured News & Press Releases
Oct 05, 2022: Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn
Sep 06, 2022: NXP002 data to be presented at the 2022 European Respiratory Society Congress
Aug 17, 2022: Arrowhead files for regulatory clearance to initiate phase 1/2a study of ARO-MMP7 for idiopathic pulmonary fibrosis
Aug 17, 2022: Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress
Aug 15, 2022: Bridge Biotherapeutics receives FDA authorization to proceed with phase 2 study of BBT-877
Aug 10, 2022: Nuformix : NXP002 successful completion of tolerability studies
Aug 03, 2022: Algernon Pharmaceuticals invited to present phase 2 IPF and chronic cough study data at 9th American Cough Conference
Aug 02, 2022: Elixiron Immunotherapeutics announces orphan drug designation granted to CSF-1R inhibitor, EI-1071 for the treatment of idiopathic pulmonary fibrosis
Jul 28, 2022: Algernon Pharmaceuticals reports additional positive data from its phase 2 study of Ifenprodil for IPF and chronic cough
Jul 20, 2022: Daewoong Pharmaceutical gets first Korean US FDA fast-track for new idiopathic pulmonary fibrosis drug
Jul 11, 2022: Pliant reports positive data from Phase IIa idiopathic pulmonary fibrosis trial
Jul 04, 2022: AD-214 program modified to maximise partnering options, extends cash runway
Jun 30, 2022: PureTech initiates late-stage clinical study of wholly-owned candidate LYT-100 (deupirfenidone) in IPF
Jun 27, 2022: Nuformix : NXP002 Update
Jun 24, 2022: Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Idiopathic Pulmonary Fibrosis - Dormant Projects, 2022
Idiopathic Pulmonary Fibrosis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW